PRESS RELEASE. Capitainer, a Swedish Medtech company that supplies intelligent solutions for self-sampling of blood and plasma, recently completed a…Read more
NEW COMPANY AT SCIETY. Most blood sampling is still performed by qualified healthcare personnel at care facilities, but new technology…Read more
The investment syndicate
Join the Sciety investment syndicate and receive personal invitations to company presentation events and be the first to get exclusive information about selected companies. Sciety membership is free and a minimum investment is SEK 100,000.
Services we offer
Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.
What our clients say
“We are very pleased with the outcome of the financing round through Sciety. The whole process was efficient and went very smoothly thanks to Sciety's competent and professional team. It was a fun and constructive collaboration.”
Malte Kühnemund, CEO Cartana
From late preclinical trial phase to Phase II clinical trials. All therapeutic areas.
From clinical validation phase to expansion phase.
From late preclinical phase to Phase II clinical trials. All therapeutic areas.
From clinical validation to expansion phase. All indications.
ICT in healthcare
From pilot phase to expansion phase. Value-enhancing healthcare.
From early sales to expansion phase. Preventive health and medical services.
Current investment opportunities
Receive information about upcoming investment opportunities
Sign up to receive information about upcoming investment opportunities and invitations to investor lunches with the companies' executive management teams.
Selection of executed investments
Capitainer supplies intelligent solutions for self-sampling of blood and plasma. The product qDBS is based on DBS (Dried Blood Spot) technology and is designed for easy home sampling of blood with high precision.
Synartro is developing a unique treatment for knee osteoarthritis by combining two proven drugs, which will offer an effective and safe alternative to today’s treatments.
PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.
Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.